News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Ariad Pharmaceuticals, Inc. Not for Sale: CEO
March 31, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Ariad Pharmaceuticals (ARIA.O), whose stock is trading at near five-year highs, is not looking to sell itself and is in partnership talks with large pharmaceutical companies in Japan for its leukemia drug, its chief executive said.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Obesity
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
June 4, 2025
·
2 min read
·
Nick Paul Taylor
Editorial
The Decadent Show of Data at ASCO25
June 3, 2025
·
2 min read
·
Dan Samorodnitsky
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
June 2, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio
June 2, 2025
·
3 min read
·
Nick Paul Taylor